depression

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J’s Spravato for depression ‘should be much cheaper’

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.

Views & Analysis

Abilify MyCite and innovating in digital health

pharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the company’s innovative digital collaboration with Pr

News

FDA approves Janssen’s ketamine-based nasal antidepressant

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted

News

FDA panel backs J&J's potential depression blockbuster

A panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal spray for depression, esketamine, bringing the medicine closer to approval.

News

NICE backs digital CBT for youngsters with depression

NICE has recommended digital cognitive behavioural therapy (CBT) should be used as a first-line treatment for children and young people with mild depression.

News

Otsuka funds prescription therapy app for depression

Otsuka is once again betting on digital as a new avenue for depression treatment by collaborating with Click Therapeutics to develop and commercialise a ‘prescriptio

J&J’s Spravato for depression ‘should be much cheaper’

Abilify MyCite and innovating in digital health

FDA approves Janssen’s ketamine-based nasal antidepressant

FDA panel backs J&J's potential depression blockbuster

NICE backs digital CBT for youngsters with depression

Otsuka funds prescription therapy app for depression

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

depression

Editor's Picks